Oruka Therapeutics, Inc. ORKA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$31.82M-51.5% | -$29.58M+64.7% | -$30.28M-5.8% | -$24.57M-10.5% | -$21M-197% | ||
| $43K+169% | $28K+3.7% | $20K+81.8% | $19K+533% | $16K+433% | ||
| $6.97M+42.7% | $4.12M-72.4% | $10.17M+4.1% | $5.08M+561% | $4.88M+5,645% | ||
| -$1.3M-156% | $2.21M-33.0% | $4.81M+191% | —— | $2.32M+200% | ||
| —— | —— | —— | —— | $60K— | ||
| -$493K-694% | $1.95M-43.8% | -$2.46M-252% | $1.12M-44.7% | $83K+1,975% | ||
| -$125K-495% | $0+100% | -$439K-7,417% | -$8K-300% | -$21K— | ||
| -$23.58M-13.0% | -$22.59M+60.9% | -$21.6M+44.6% | -$23.15M-107% | -$20.87M-12,322% | ||
| $73K+462% | $63K-66.7% | $99K-42.1% | $34K— | $13K— | ||
| $90.83M+105% | $100.99M-69.4% | $267.68M— | $108M— | $44.29M— | ||
| $76.47M-12.3% | $79.03M— | $145.33M— | $112.89M— | $87.17M— | ||
| $29.15M+46.3% | $27.64M-63.2% | $28.99M+12.8% | $24.09M+29.0% | $19.93M+284% | ||
| -$14.44M-134% | -$22.02M+93.3% | -$122.45M-71,508% | $4.86M— | $42.87M— | ||
| $1.7M— | $562K+941% | —— | —— | —— | ||
| $40.6M— | $298K-99.9% | $169.91M-62.2% | —— | —— | ||
| $2.59M-88.2% | -$44.32M-172% | $25.86M-93.7% | -$18.18M-220% | $22M+1,540% | ||
| $446K-75.2% | $663K-70.5% | $1.04M— | $1.5M— | $1.8M— | ||
| $6.97M+42.7% | $4.12M-72.4% | $10.17M+12.9% | $5.08M+643% | $4.88M+5,645% | ||
| $43K+169% | $28K+3.7% | $20K+81.8% | $19K— | $16K— | ||
| $3M+158% | $0-100% | -$111K-102% | -$698K-105% | -$5.21M-189% | ||
| -$1.3M-156% | $2.21M-33.0% | $4.81M+191% | —— | $2.32M+200% | ||
| -$125K-495% | $0+100% | -$439K-7,417% | -$8K-300% | -$21K— | ||
| -$493K-694% | $1.95M-43.8% | -$2.46M-252% | $1.12M-44.7% | $83K+1,975% | ||
| -$461K-411% | $805K-28.6% | $2.4M+21.3% | $617K-64.1% | $148K— | ||
| —— | —— | —— | —— | —— | ||
| $38.9M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3M+41.4% | —— | —— | —— | $2.12M— | ||
| $7.29M+41.2% | $6.79M-48.0% | $5.12M+36.2% | $4.34M+54.0% | $5.16M+209% | ||
| —— | $13.5K-82.2% | $13.5K— | $13.5K— | $13.5K— | ||
| —— | $237.25K+132% | $237.25K— | $237.25K— | $237.25K— | ||
| $4.61M+12.6% | $4.85M-17.3% | $3.83M+188% | $3.86M— | $4.09M— | ||
| $143K+131% | —— | —— | —— | $62K— | ||
| $4.61M+12.9% | $4.85M+10.2% | $3.83M+363% | $3.86M+614% | $4.09M+2,010% | ||
| -$1.03M-3,031% | $361K+980% | $212K— | -$21K— | $35K— | ||
| —— | $2.52M-75.7% | $2.52M— | $2.52M— | $2.52M— | ||
| -$23.65M-13.3% | -$22.66M+61.0% | -$21.7M+44.6% | -$23.18M— | -$20.88M— | ||
| -$23.65M-13.3% | -$22.66M+61.0% | -$21.7M+44.6% | -$23.18M— | -$20.88M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Oruka Therapeutics, Inc. generate?
- Oruka Therapeutics, Inc. (ORKA) generated -$90.9M in operating cash flow over the trailing twelve months.
- What is Oruka Therapeutics, Inc.'s free cash flow?
- After $269.0K of capital expenditures, Oruka Therapeutics, Inc.'s free cash flow was -$91.2M over the trailing twelve months, up 23.6% year over year.
- Where does Oruka Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.